Your browser doesn't support javascript.
loading
Measuring Erosion of Biodegradable Polymers in Brimonidine Drug Delivery Implants by Quantitative Proton NMR Spectroscopy (q-HNMR).
Wang, Hongpeng; Roof, Mike; Burgher, Kyle; Pham, Chiem; Samuels, Eric R; He, Yan; Jian, Huahua; Wang, Tao.
Afiliación
  • Wang H; Analytical Research and Development, AbbVie, 2525 Dupont Drive, Irvine, CA 92612, USA. Electronic address: Hongpeng.wang@abbvie.com.
  • Roof M; Analytical Research and Development, AbbVie, 2525 Dupont Drive, Irvine, CA 92612, USA.
  • Burgher K; Analytical Research and Development, AbbVie, 2525 Dupont Drive, Irvine, CA 92612, USA.
  • Pham C; Drug Product Development, AbbVie, 2525 Dupont Drive, Irvine, CA 92612, USA.
  • Samuels ER; Analytical Research and Development, AbbVie, 2525 Dupont Drive, Irvine, CA 92612, USA.
  • He Y; Analytical Research and Development, AbbVie, 1 N. Waukegan Road, North Chicago, IL 60064, USA.
  • Jian H; Analytical Research and Development, AbbVie, 2525 Dupont Drive, Irvine, CA 92612, USA.
  • Wang T; Analytical Research and Development, AbbVie, 2525 Dupont Drive, Irvine, CA 92612, USA.
J Pharm Sci ; 2024 Aug 31.
Article en En | MEDLINE | ID: mdl-39218154
ABSTRACT
Erosion of biodegradable polymeric excipients, such as polylactic acid (PLA) and polylactic-co-glycolic acid (PLGA), is generally characterized by microbalance for the remaining mass of PLA and/or PLGA and Gel Permeation Chromatography (GPC) for molecular weight (MW) decrease. For polymer erosion studies of intravitreal sustained release brimonidine implants, however, both microbalance and GPC present several challenges. Mass loss measurement by microbalance does not have specificity for excipient polymers and drug substances. Accuracy of the remaining mass by weighing could also be low due to sample mass loss through retrieval-drying steps, especially at later drug release (DR) time points. When measuring the decrease of polymer MW by GPC, trace amounts of polymeric degradants (oligomers and/or monomers) trapped inside the implants during DR tests may not be measurable due to sensitivity limitations of the GPC detector and column MW range. Previous efforts to measure remained PLGA weight of dexamethasone micro-implants using qNMR with external calibration have been performed, however, these measurements do not account for chemical structure changes (i.e. LA to GA ratio changes from time zero) of PLGA implants during drug release tests. Here, a qNMR method with an internal standard was developed to monitor the following changes in micro-implants during drug release tests 1. The remaining overall PLA/PLGA mass. 2. The remaining lactic acid (LA), glycolic acid (GA) unit and PLGA's lauryl ester end group percentages. 3. The trace content of PLA/PLGA oligomers as degradants retained in the implants. Unlike microbalance analysis, qNMR has both specificity for drug substance, excipient polymer, and accuracy due to minimal implant loss during sample preparation. Compared to the overall PLA/PLGA remaining mass generally monitored in erosion studies, the percentage of remaining LA, GA, and the ester end group provide more information about the microstructure change (such as hydrophobicity) of PLA/PLGA. Additionally, the qNMR method can complement GPC methods by measuring the change of remaining PLA and PLGA oligomer concentrations in brimonidine implants, with tenfold less sample and no MW cutoff. The qNMR method can be used as a sensitive tool for both polymer excipient characterization and kinetics studies of brimonidine implant erosion.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Pharm Sci Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Pharm Sci Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos